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At 5.5 years, initial SNM therapy was less costly ($23,504 vs. $27,720) and more
effective than initial BTX (4.08 vs. 4.04 QALYs). Probabilistic sensitivity analyses
that varied SNM and BTX success and repeat BTX injection probabilities and utili-
ties, confirmed these results. Repeat injections and differences in AEswere respon-
sible for most of the changing costs over time. CONCLUSIONS: Based on a more
clinically comprehensive design and set of inputs than previousmodels, treatment
with SNM may be more cost-effective than BTX, especially over longer periods of
time.
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OBJECTIVES: Hyperphosphatemia leads to increased hospitalizations and mortal-
ity in End-Stage Renal Disease (ESRD). First-line therapy in Canada consists primar-
ily of calcium carbonate (CC). We determined the incremental cost-effectiveness
ratio (ICER) of the non-calcium phosphate binder lanthanum carbonate (LC) as
second-line therapy, from a Canadian healthcare perspective. METHODS: A
Markov model was developed to determine the cost-effectiveness of second-line
LC after therapy failure on CC, compared with continued CC treatment; or alterna-
tively with second-line Sevelamer (SH). Patient-level data (n380) from a prospec-
tive randomized trial were used for LC and CC drug efficacy. For SH efficacy, an
indirect comparison of eight clinical trials was used to calculate a dose-relativity
between SHand LC of 2.7:1. Costs, quality of life,mortality andhospitalization rates
were based on Canadian data. Univariate and probabilistic sensitivity analyses
were performed. RESULTS: Modelling 1,000 dialysis patients, 378 (37.8%) did not
achieve target serum phosphate (SP) levels (1.78 mmol/L) with first-line CC ther-
apy and were eligible for LC. Of these, 168 (44.4%) responded to LC therapy, result-
ing in 49 life years and 29 Quality-adjusted life years (QALYs) gained. The ICER of
second-line LC treatment comparedwith continuedCC treatmentwasCAN$13,200
($4,600-$22,800) per QALY gained. Results were robust to plausible variations in
model parameters. One-year drug costs per additional responder to second-line LC
therapy were $2,600, compared to $4,300 for first-line LC. The model evaluating
second-line use of LC vs second-line use of SH estimated that LC had similar effi-
cacy but was 16% less expensive than SH. CONCLUSIONS: Second-line treatment
with LC is cost-effective compared to continued therapy with CC; and is less ex-
pensive compared to first-line LC. LC had lower costs compared with SH, due to
lower dose requirements for similar efficacy. These results reinforce current treat-
ment guidelines to treat patients not achieving target SP levels on CC with second-
line LC.
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OBJECTIVES: Cytomegalovirus (CMV) disease can severely impact patient out-
comes and costs associated with kidney transplant. The IMPACT study has shown
that kidney transplant patients significantly benefit from extending valganciclovir
prophylaxis from 100 to 200 days. The objective of this study was to determine the
cost-effectiveness of valganciclovir 200 day prophylaxis compared to 100 days in
kidney transplant patients at high-risk for developing CMV disease. METHODS: A
Markov model was developed to capture time spent by patients in various health
states, which included: CMV, No-CMV, Acute Rejection, Graft Failure, Dialysis and
Death. Results were reported as incremental cost per additional quality adjusted
life-years (QALY) gained, over a 10-year period. Transition probabilities for the first
year were derived from the IMPACT study. Data beyond the first year were derived
from the published literature and baselinemortality rate was determined from the
Canadian Organ Replacement Register. The base case analysis focused on direct
medical costs only from the perspective of the Ministry of Health (MoH). A second
analysis was conducted from the societal perspective. Cost data were obtained
froma variety of sources and reported as 2010 CanadianDollars. A 5%discount rate
was applied to both costs and patient outcomes. Multiple sensitivity analyses were
undertaken to test the robustness of the model. RESULTS: From the MoH perspec-
tive valganciclovir 200 days prophylaxis is cost-effective when compared to 100
days with an incremental cost-utility ratio (ICUR) of $34,818 per additional QALY
gained. The cost-effectiveness is improved from the societal perspective, with an
ICUR of $32,571 per additional QALY gained. Results were robust over a wide range
of sensitivity analyses tested. CONCLUSIONS: Valganciclovir 200 days is a cost-
effective prophylaxis strategy in kidney transplant patients at high-risk of devel-
oping CMV when compared to valganciclovir 100 days.
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OBJECTIVES: The rate and extent of utilization of IV iron in anemic CKD patients
was quantified. Predictors of IV iron and ESAusewere determined. The impact of IV
iron and ESA use was examined separately for total hospital costs and length of
stay (LOS).METHODS: This is a retrospective cohort analysis within the UHC data
warehouse in the period of January 1, 2006, to December 31, 2008. Inclusion criteria
were age  18 years with a primary/secondary diagnosis of CKD. The exposure of
interest was IV iron and ESA therapy, and the outcome was the difference in total
hospital costs and length of stay. A binomial logistic regression using the GEE
methodology was used to identify predictors of IV iron utilization. Propensity
scores were used to control for confounding. A GEE model using gamma distribu-
tion and log link was used to determine the adjusted hospital cost and length of
stay for the IV iron and ESA and ESA alone therapy groups. RESULTS: 82,947 pa-
tients met the study criteria. Of the 82,947 CKD patients on ESA therapy, only 8%
(n  6678) patients were on IV iron supplementation. Age, race, primary payer,
admission status, severity of illness, dialysis status and physician specialty were
identified as strong predictors of IV ironuse. For patients using both IV iron and ESA
(n6678), mean costs were $34,756 compared to $31,404 for ESA users alone
(n76,269). The overall mean LOS for all patients was 9.75 days. For those using IV
iron, the LOS was 10.71 days, and for those only using ESA, the LOS was 9.66 days.
CONCLUSIONS: Our investigation showed significant reduction in ESA doses with
the use of IV iron supplementation, however, the overall prevalence of IV iron
usage was low. Intravenous iron users were associated with a higher total hospital
cost and longer length of stay than ESA users.
Urinary/Kidney Disorders – Patient-Reported Outcomes & Preference-Based
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OBJECTIVES: The aim of our study was to construct the conceptual framework of
the impact of ADPKD on patients to support the use or development of a HRQoL
instrument in ADPKD.METHODS: Based on concepts identified from the literature
and ADPKD physicians/researchers from North America, Europe, and Japan, pa-
tients were asked how ADPKD impacts their physical and social functioning, emo-
tions, and urinary symptoms according to a pre-defined moderator guide. Twenty
focus groups (FGs) were conducted across 11 sites: three cities in North America
(n42), six cities in Europe (n64), and two cities in Japan (n11). FGs were mod-
erated by native speakers and overseen onsite by a US-based scientist. A saturation
table was developed to summarize concepts discussed in the FGs; saturation was
achieved once no new concepts were identified. Concepts were identified based on
themes mentioned by 2 participants within a FG. RESULTS: Concepts generated
from the literature and ADPKD physicians/researchers discussions were endorsed
by ADPKD patients. Agreement of concepts between genders across all countries
was observed. Twenty-eight concepts were identified and categorized into: Physi-
cal Impact (impact on work/housework, limited functioning with mild/moderate
exertion, self-care, diminish sex/intimacy, pain/discomfort in extremities/core,
pain affecting work/housework, pain occurring with activity, modifications in life-
style), Emotional Impact (fatigue, depression, anxiety, guilt of passing it to children,
acceptance/self-education), Urinary Concerns (urgency, frequency, nocturia).
Other concepts identified by patients include effect on diet, concern over body
image, thirst, and disruption of social/leisure activities. Fifty-seven percent of
these concepts were identified in the first FG; 100% saturation was achieved in the
fifth FG. CONCLUSIONS: Identified concepts were universally applicable and their
strength is evident by the achievement of complete saturation after 25% of the FGs.
The completion of this conceptual framework using an iterative process provides a
strong basis to develop an ADPKD-specific HRQoL instrument.
Urinary/Kidney Disorders – Health Care Use & Policy Studies
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OBJECTIVES: The aim of this study was to characterize Brazilian-specific immuno-
suppressant (IS) treatment patterns among kidney transplant patients.METHODS:
Non-interventional, multicenter, medical chart review of patients undergoing kid-
ney transplant. Five year follow-up data on IS medication use from adult ( 18
years old at time of transplantation), single kidney only transplants from Jan/2004
to Jan/2005 were collected from 7 transplant center in Brazilian hospitals. Patients
were censored on graft loss or loss of follow-up. RESULTS: Data on 498 patients
were included; 51.2%were female, the, average age was 38.913.9 years, and 55.4%
was recipients of kidneys from deceased donors. Of the 498 patients, 61.2% were
treatedwith tacrolimus (TAC)-based IS regimens as the initial calcineurin inhibitor
(CNI), while 38.8%were treatedwith cyclosporine (CyC). CNI switching fromTAC to
CyC occurred in 4.6%, versus 5.6% that switched from CyC to TAC. There was a
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decreasing trend in average CNI dose by year: at the end of the first year, the mean
dose of TAC was 9.35.4 mg/day and 282.1118.3 mg/day for CYC, decreasing to
5.23.6 and 158.757.8 mg/day in the third year, and 4.87.3 and 144.258.4 mg/
day in the fifth year. At the end of the first (n455) and second year (n408) post-
transplant, the most common IS regimens were TAC/prednisone/mycophenolate
mophetil (MMF) (19.1% in both years), TAC/prednisone/azathioprine (15.6% at first
year and 14.7% at second year) and CyC/prednisone/azathioprine (13.2% at first
year and 14.0% at second year). By the end of the fifth year (n141), however, the
most common IS regimen was TAC/prednisone/mycophenolate sodium (MFS;
31.9%), followed by CyC/prednisone/MFS (7.8%) and TAC/prednisone/MMF (7.1%).
CONCLUSIONS:Tacrolimuswas the CNI of choice for themajority of de novo kidney
transplant patients in 2004. The main IS therapy regimens during the first post-
transplant years was tacrolimus/prednisone/mycophenolate mophetil.
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OBJECTIVES: The employer burden of CKD in terms of lost productivity, short and
long term disability use, and high total health care costs has been well-docu-
mented and warrants an employer-sponsored population health management
program to improve the health and lives of theworkforce. Georgia Power Company
(GPC) has implemented a chronic care management program aimed at early iden-
tification, disease awareness, and counseling of employees through on-site
screenings. METHODS: Individuals are offered voluntary participation in the CKD
management programwith their PCPs andnephrologists depending upon their risk
and CKD stage. Health outcomes including, clinical, resource utilization, and self-
reported health status and productivity are compared pre- and post- program
implementation. RESULTS: Preliminary results at the 6-month mark show that: a)
2,589 employees were screened, 638 (25%) met program criteria for participation
and 110 (17.2%) agreed to participate in the study; b) among the current enrollees,
17% have diabetes and 51% have hypertension; c) mean eGFR rates are 61.27, and
HbA1C levels of 7.7, and a mean BMI of 30.5 indicating a population at high risk for
developing CKD; d) participants reported missing on average 10.5 hours/week due
to their CKD; and e) baseline total health care expenditures were $19,776 permem-
ber per year indicating a high cost population as well. CONCLUSIONS: CKD is a
high-cost disease for GPC. Resources invested in creating novel CKD management
programs to identify, raise awareness, and manage CKD are a worthwhile invest-
ment for employers.
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OBJECTIVES:Many patients with OAB attempt self-management and are reluctant
to initiate an OAB discussion with a physician. We sought to identify patient char-
acteristics associatedwith patient initiation of anOAB discussionwith a physician.
METHODS: Of 24,866 respondents of the 2009 National Health & Wellness Survey,
an internet-based questionnaire onhealthcare attitudes, behaviors, and outcomes,
2750 recontacted respondents qualified for and completed a longitudinal survey.
Eligible subjects (18 y) had an OAB Awareness Total score of 14 (men) or 16
(women) or used an OAB prescription medication. Exclusion criteria included cur-
rent pregnancy or catheter use, hematuria, urinary tract infection symptoms, be-
nign prostatic hyperplasia (BPH), use of BPH medication, or prostate cancer. Anal-
ysis of proportions and logistic regression analysis (2-tailed P0.05 significance
level) identified patient characteristics associated with initiation of OAB discus-
sions with a physician. RESULTS: 1325 of 2750 (48%) OAB patients reported initiat-
ing an OAB discussion with a physician. These respondents (mean age 52 y) were
predominantly female (65%) and white (71%). Significant variables associated with
initiation of an OAB discussion were divorced/separated/widowed vs single, more
familiar with OAB, a longer duration of bladder control symptoms, lower SF-12
Physical Component Summary score, better daily activity function, greater pill
burden, and regular physician contact (Table). Patient age, income, employment
status, and health insurance coverage were not significantly associated with a
patient-physician OAB discussion. CONCLUSIONS: Patients are more likely to ini-
tiate an OAB discussion with their physician if they have regular contact with the
physician, a longer duration of symptoms, are familiar with OAB, and have worse
physical quality of life. Socioeconomic variables or drug insurance coverage were
not significantly associated. These findings suggest that the physician relationship
is important for help seeking behavior; and there is a need for early patient educa-
tion on OAB symptoms and treatments.
Urinary/Kidney Disorders – Research on Methods
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OBJECTIVES: Determine the impact of correcting for different definitions of pros-
tate-specific antigen (PSA) recurrence when analyzing relative effectiveness of
seven treatments for localized PC; Emphasize the importance of clinical input and
real-world data in ensuring modeling accuracy. METHODS: We conducted two
lifetime cost-utility analyses comparing men undergoing open, laparoscopic, or
robot-assisted radical prostatectomy, 3-dimensional conformal or intensity-mod-
ulated radiation therapy, brachytherapy, or combined external-beam radiation
and brachytherapy.We constructed aMarkovmodel quantifying lifetime costs and
quality-adjusted life years (QALYs) for men with localized PC in low-, intermedi-
ate-, and high-risk strata. Post-treatment PSA recurrence is defined differently for
surgical versus radiation treatments. In Study 1, we made clinically-based correc-
tions in time between recurrence and metastasis, the basis for time-to-disease-
progression (biochemical failure [BCF]) calculations, to account for the different
definitions. In Study 2, these corrections were not made. RESULTS: In “corrected”
analyses, surgery tended to yieldmore QALYs and lower costs than radiation, with
minimal differences among surgicalmodalities. Compared to a base case assuming
a 4-year increment between the surgery and radiation modalities in the median
time from BCF to metastasis, “uncorrected” analyses yield surgical costs relatively
overstated by 3 to 11%; QALYs understated by 1 to11%; life expectancy understated
by1% to 8.5%;metastasis overstated by 17 to 36%; and PC death overstated by 17%
to 43%. Results are generally greater with larger corrections and outcomes dis-
counted to net present value. CONCLUSIONS: “Without correction” results do not
affect conclusions about relative costs for all patients or QALYs for low-risk pa-
tients. They do affect QALY conclusions for intermediate- and higher-risk patients,
yielding erroneous conclusions on the relative superiority of radiation versus sur-
gical treatments. Without correction, the same incorrect conclusions would be
reached for survival, metastasis, and PC death. Literature and real-world datawere
used to validate the corrections.
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OF ONABOTULINUMTOXINA IN PATIENTS WITH NEUROGENIC DETRUSOR
OVERACTIVITY
Globe D1, Carlson J2, Patel H3, Colayco D1, Hansen RN2, Watanabe J2, Sullivan SD2
1Allergan LLC, Irvine, CA, USA, 2University of Washington, Seattle, WA, USA, 3Allergan, LLC,
Marlow Buckinghamshire, UK
OBJECTIVES: Selection of an appropriatemodeling structure is a key consideration
in economic evaluations. Factors that influence the choice of modeling structure
include data availability and consensus within the clinical community regarding
clinically meaningful definitions of treatment response and defined and measure-
able health states. In the absence of an agreed consensus, selecting a model struc-
ture is challenging. We explored twomodel structures to assess the cost-effective-
ness of onabotulinumtoxinA for the treatment of urinary incontinence (UI) due to
neurogenic detrusor overactivity (NDO).METHODS: Themerits and limitations of a
model based on treatment response versus an absolute model structure were con-
sidered. In the response model, health states were defined by precise trial out-
comes (percent reduction in UI episodes from baseline). In the absolute model,
health states were defined by categories of UI episodes/week. In the absence of
clinically meaningful cutoffs, we plotted health-related quality of life (HRQoL)
scores versus UI episodes to derive meaningful cutoffs for health states based on
HRQoL. RESULTS: In the response model, response was defined as a 50% reduc-
tion in UI episodes. The primary limitation with this approach is the heterogeneity
within ‘non-responder’ patients (e.g. patients with either a 0% or a 49% reduction
are both ‘non-responders’). No clear health state cutoffs were observed with re-
spect to HRQoL and UI episodes for the absolute model. Health states were defined
on percentile distribution within the trial population: dry, 0-25% [1-14 UI episodes/
week],25%-75% [15-32 UI episodes/week], and75% [32 UI episodes/week]. The
primary limitations to this approach are the inability to capture health improve-
ment within health states and the lack of clinical relevance for health states based
on percentiles. CONCLUSIONS: In the absence of clinical consensus, model struc-
ture selection should be a key consideration to capture the true economic value of
a therapy.
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Wilson SM, Rubin JL
DaVita Clinical Research, Minneapolis, MN, USA
OBJECTIVES: Retrospective analyses are inherently subject to bias. Techniques
such as propensity score matching (PSM) can function as pseudo-randomization.
The PSM, however, is often done solely using administrative claims data.We tested
the hypothesis that claims alone would provide inadequate matching when com-
pared to claims plus relevant biomarkers. METHODS: We used databases from a
large dialysis organization to obtain two cohorts of dialysis patients prescribed
different drug therapies within the same class. The cohorts were first matched on
demographics and comorbidities only. The same cohorts were then rematched,
adding baseline biomarkers (albumin, corrected calcium, Kt/V, normalized protein
catabolic rate (nPCR), parathyroid hormone (PTH), phosphorus) to the PSM. We
used generalized mixed models (GMM) to determine if treatment was associated
with lab outcomes over a 16-week period, run separately on both PSM cohorts.
RESULTS: The first PSM cohorts did not differ on baseline demographic and comor-
bid variables, but significant differences existed in four (nPCR, phosphorus, cal-
cium, PTH) of the six baseline biomarkers excluded from the match (all p 0.01).
When biomarkers were included in the PSM, there were no significant differences
between groups on any baseline measures. GMM analysis showed a significant
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